Leronlimab - CytoDyn
Alternative Names: PA-14; PRO-140; Vyrologix®Latest Information Update: 16 Jun 2026
At a glance
- Originator Progenics Pharmaceuticals
- Developer CytoDyn; Progenics Pharmaceuticals; Syneos Health; Weill Cornell Medicine
- Class Anti-inflammatories; Antidementias; Antineoplastics; Antiretrovirals; Antivirals; Hepatoprotectants; Immunotherapies; Monoclonal antibodies; Vascular disorder therapies
- Mechanism of Action CCR5 receptor antagonists; Virus internalisation inhibitors
-
Orphan Drug Status
Yes - Graft-versus-host disease
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Registered Triple negative breast cancer
- Preregistration COVID 2019 infections; HIV infections
- Phase II Alzheimer's disease; Colorectal cancer; Inflammation; Non-alcoholic steatohepatitis; Post acute COVID 19 syndrome; Solid tumours
- Preclinical Glioblastoma
- Suspended COVID-19 pneumonia
- Discontinued Graft-versus-host disease; HIV-1 infections; Multiple sclerosis; Stroke; Traumatic brain injuries
Most Recent Events
- 30 Apr 2026 Phase-II clinical trials in Alzheimer's disease (Early-stage disease) in USA (SC) (NCT07553338)
- 28 Apr 2026 Weill Medical College of Cornell University plans phase II SALIENT-AD trial in Alzheimer's Disease in US (Parenteral) (NCT07553338)
- 22 Apr 2026 Preliminary efficacy, safety and pharmacodynamics data from the phase II CLOVER trial in Colorectal cancer released by CytoDyn